Articles tagged with Ovarian Cancer
Researchers found that former smokers have higher CC10 levels than current smokers, which may help explain the lower risk of lung cancer among quitters. Additionally, first-degree relatives of never-smoking lung cancer patients are at increased risk of cancer and early diagnosis compared to healthy never-smokers.
A pilot study found elevated Bcl-2 levels in patients with ovarian cancer, associated with 92% of cases, while CA125 tests identified only 68%. The research aims to develop a safe, non-invasive detection method for ovarian cancer.
Researchers have identified a multi-marker panel of 20 proteins that correctly recognize over 98% of serum samples from women with ovarian cancer, offering higher diagnostic power than any other published assay. The study uses novel technology to analyze multiple proteins in a single drop of blood or serum and aims to develop this scre...
A new study provides guidelines to help doctors evaluate common test abnormalities and detect ovarian cancer with precision in asymptomatic postmenopausal women. The criteria use ultrasound and CA-125 tests to identify high-risk women, resulting in accurate detection of malignancy in over 100% of cases.
A new trial combining thalidomide and topotecan shows a 47% overall response rate, compared to 21% for topotecan alone. Women treated with the combination had improved disease-free survival and trended towards increased overall survival.
Biologists at Brown University and the University of California–Berkeley have discovered a critical role for two proteins – TAF4b and c-Jun – in the growth and nurturing of granulosa cells that surround eggs. The finding provides important new information about fertility and may lead to better in-vitro fertilization therapies.
Researchers found that a nitric oxide-releasing aspirin derivative, NCX-4016, reacts with thiols in ovarian cancer cells to stop proliferation and increase susceptibility to chemotherapy. This treatment may offer new hope for patients with resistant ovarian cancer.
Research found no significant association between hospital case volume and short-term mortality after ovarian cancer surgery. However, patients treated by gynecologic oncologists had the best outcomes and lowest mortality rates. Long-term outcomes were slightly more favorable for high-volume hospitals, but this difference was modest.
Women with Lynch syndrome have an equal risk of developing endometrial and colon cancers, and are at high risk for additional cancers. Prophylactic surgeries, such as hysterectomy and ovary removal, significantly reduce the risk of these two gynecological cancers.
A study by Mayo Clinic researchers found that aggressive surgery greatly improves survival rates for patients with the most severe disease spread. Radical surgery was shown to improve five-year survival rates by 44% compared to non-radical surgery, indicating it aids in survival rather than increasing risk.
The National Cancer Institute has issued a clinical announcement recommending a combination of chemotherapy regimens for women with advanced ovarian cancer. The treatment involves delivering chemotherapy directly into the abdominal cavity (intraperitoneal, or IP) in addition to traditional IV chemotherapy. This approach appears to be m...
A new study confirms the survival benefit of intra-abdominal chemotherapy, also known as intraperitoneal (IP) chemotherapy, for most women with advanced ovarian cancer. The treatment has shown an overall survival period of approximately one year after optimal debulking surgery.
A seven-year study of over 400 patients found that delivering chemotherapy directly into the abdomen via a catheter increases survival and relapse-free survival rates compared to intravenous chemotherapy alone. However, side effects are significantly worse for the abdominal group.
UCSD researchers found a strong association between vitamin D deficiency and higher rates of colon, breast, and ovarian cancers. They recommend increasing the public's intake of vitamin D3 to 1,000 IU/day to reduce cancer incidence, which could lead to thousands of premature deaths annually.
A recent study published in the Journal of the National Cancer Institute found that screening chest x-rays can detect early-stage lung cancers at high rates. The study involved 77,465 participants and showed a significant reduction in lung cancer mortality among current smokers, with a detection rate of 6.3 cases per 1000 individuals.
A large population-based cohort of Swedish women found a significant association between tea consumption and reduced risk of ovarian cancer. Women who drank two or more cups of tea per day had a 46% lower risk compared to non-drinkers.
A large study found an increased risk of second cancers in various sites, including connective tissue and myeloid leukemia, after breast cancer diagnosis. Treatment for breast cancer and shared genetic or environmental factors are thought to contribute to this risk.
Researchers developed a genetic profile of ovarian cancer that predicts survival and identifies key genes involved in chemotherapy response. The study used microarray analysis to identify a gene expression profile known as the Chemotherapy Response Profile, which confirms the importance of genes such as BAX.
Research suggests that adding these foods to the diet can prevent or halt cancer growth. Broccoli sprouts were found to reduce Helicobacteri pylori infection and alleviate gastritis in infected individuals.
Researchers have found that combining the monoclonal antibody C225 with photodynamic therapy in a mouse model of ovarian cancer resulted in substantial tumor reduction and improved survival rates compared to single-agent treatments. This innovative approach may provide new hope for women diagnosed with this aggressive form of cancer.
African American women face unique genetic challenges in breast cancer screening due to limited data on mutations. Research confirms that genetic testing models work just as well for African Americans as they do for other populations, but the spectrum of mutations is vastly different.
A study by Mayo Clinic researchers found that radical surgery significantly improves five-year survival rates for patients with ovarian cancer and diaphragm disease. The procedure resulted in a 55% survival rate compared to 28% for those who did not undergo surgery.
The new center aims to develop nanomaterials and nanodevices for cancer diagnostics, therapeutics, drug delivery, imaging, and monitoring applications. Researchers will focus on developing early detection tools, targeting cancer cells with chemotherapeutic agents, and creating new classes of drugs.
Researchers have found a surge in Rsf-1 gene copies in 13.2% of high-grade ovarian cancers, but not in low-grade or benign tumors. The amplification is associated with poorer survival rates, and the Hopkins scientists are working to develop targeted therapies.
A new protocol has been developed to identify women with high-risk family histories of breast or ovarian cancer, allowing for more accurate data collection and analysis. The study found that 20.6% of participants had elevated risk levels, with higher rates among those with Ashkenazi Jewish ancestry.
A study found that a thorough family history is an effective measure for cancer risk, with 20% of women with breast or ovarian cancer having a high risk of BRCA1/BRCA2 mutations. Women of Ashkenazi ancestry were more likely to have high-risk family histories than those of non-Ashkenazi ancestry.
A study of 199 families with multiple cases of breast cancer found that women from these families do not have an increased risk of ovarian cancer. Despite this, the genetic mechanism for up to half of hereditary breast cancer remains unknown, prompting ongoing research at Memorial Sloan Kettering Cancer Center.
The US Task Force does not recommend routine screening for breast cancer gene mutations in women without a specific family medical history. However, they do suggest screening for women with a history of Ashkenazi Jewish descent, young-onset breast cancer, or multiple relatives with breast and ovarian cancer.
A study found that the BRCA2 gene mutation significantly increases cancer risk in men, with higher rates of prostate, pancreatic, pharyngeal and bone cancers. The mutation is associated with an increased risk of developing these cancers, particularly among younger men.
Researchers found that women with ovarian cancer were more likely to present to physicians with abdominal swelling or pelvic pain up to 12 months before diagnosis. Diagnostic testing showed only a minority of patients received necessary tests, highlighting the need for earlier detection.
Researchers discovered a potential biomarker, PKCi, which predicts outcome in non-serous ovarian cancer when combined with Cyclin E. High levels of the protein correspond to reduced survival rates.
Researchers have found that nearly 42% of ovarian cancer patient tumor tissues contain alterations in the protein km23. This discovery suggests km23 as a possible diagnostic indicator and therapeutic target for ovarian cancer. Further studies aim to develop a screening test and targeted therapies using km23.
A meta-analysis of epidemiological studies found a positive correlation between milk consumption and an increased risk of ovarian cancer. High intakes of dairy foods and lactose may contribute to this association, with a 13% increase in risk seen for every 10 grams of lactose consumed daily.
A study published in the International Journal of Cancer has found three proteins present in the blood of women with breast and ovarian cancer, but not in those without cancer. This breakthrough could lead to a simple blood test for early detection and improved patient outcomes.
Strong social attachments are associated with lower IL-6 levels, reduced mortality risk, and better quality of life among women with advanced ovarian cancer. Women with weak social connections have higher IL-6 levels, which promotes tumor growth and disease progression.
Researchers found a decreased risk of certain types of ovarian tumors with moderate recreational physical activity, but not others. Physical activity also regulates hormone and growth factor levels, reducing ovarian cancer risk by affecting obesity.
A study at the American Society of Clinical Oncology meeting found that a targeted cancer drug combined with low-dose chemotherapy shrinks ovarian cancer tumors in nearly half of patients. The treatment also slows disease progression and achieves stable disease in 59% of patients.
A study led by Daniel W. Cramer found that high blood levels of antibodies against MUC1 protein are associated with lower incidence of ovarian cancer. These events include bone fractures and gynecological surgeries, suggesting a potential link between immune system activation and cancer protection.
A mathematical model suggests adjusting biometric identification systems can increase chances of catching known criminals at ports of entry by up to 94.9%. Human modification of Earth's water cycle through deforestation and irrigation may have regional impact on weather patterns and food production.
Researchers at Yale University have developed a new blood test for ovarian cancer screening using four biomarkers, showing high sensitivity and specificity. The test predicts cancer in patients whose levels of two or more biomarkers fall within a certain warning area.
A study by Vanderbilt University researchers found that inhibiting COX-1 slowed the growth of epithelial ovarian tumors in a mouse model. This breakthrough suggests targeting COX-1 as a novel approach to prevent and treat ovarian cancer.
A study by Fox Chase Cancer Center researchers identified a subset of ovarian cancer patients who respond to Iressa, a targeted therapy. The team found that mutations in the EGFR tyrosine kinase portion of the receptor can make tumors more susceptible to the drug, potentially leading to improved treatment outcomes for some patients.
RAD001 targets mTOR enzyme in high-AKT activity ovarian cancer cells, arresting cell division and reducing angiogenesis. The treatment may be combined with chemotherapy to kill weakened cancer cells.
A clinical trial found that systematic aortic and pelvic lymphadenectomy improved progression-free survival, but not overall survival, in patients with advanced ovarian cancer. The procedure did not significantly increase median overall survival duration.
Researchers found that capsaicin, a compound in red chili pepper, exhibited anticancer activity against pancreatic cancer cells. Phenethyl isothiocyanate (PEITC), a constituent of cruciferous vegetables like broccoli, also showed therapeutic benefits in inhibiting ovarian cancer cell growth.
Researchers discovered that shape-altering genes, known for their role in embryonic development, direct ovarian cancer cells to take on various forms. These unique shapes make each form of ovarian cancer distinct from one another and the surface epithelium.
Women with a family history of breast or ovarian cancer are more likely to receive genetic counseling if they're white. African American women are less aware of genetic testing technology and underestimate their cancer risk. The study found a significant racial disparity in the use of BRCA1/2 testing, which is not explained by socioeco...
USC researchers found that the BRCA1 gene disrupts interactions between different cell types, leading to ovarian cancer. The gene's indirect action may lead to new treatment options by targeting a biochemical mediator.
A study by Yale University reveals that 0.8% of women with non-invasive breast cancer (DCIS) have BRCA1 mutations, while 2.4% have BRCA2 mutations, similar to those found in more advanced breast cancers. Women with these mutations are at higher risk for early detection and may benefit from high-risk screening protocols.
Researchers have found that a combination of surgery and intraperitoneal hyperthermic chemotherapy (IPHC) improves overall survival and quality of life in patients with tumors of the appendix, small bowel, ovarian cancer, colon, rectum, stomach, and mesothelioma. The treatment has been shown to be effective for high-grade and low-grade...
A study found that the experimental test's effectiveness was undermined by technical issues and biological implausibility, casting doubt on its potential as a reliable diagnostic tool. The researchers emphasize the need for standardized protocols in proteomics research to ensure reproducibility of results.
A new study found that blocking VEGFR-3 prevented lymphangiogenesis in a mouse model, potentially inhibiting tumor metastasis. The study suggests that targeting VEGFR-3 may be a viable therapeutic strategy to prevent lymphatic vessel growth and tumor spread.
Researchers from USC found evidence that progesterone signaling influences ovarian cancer risk, particularly two haplotypes (4-D and 4-E) that increase risk by almost 3.5-fold in women who carry them. The study's findings suggest that subtle changes in the progesterone receptor gene may decrease its efficiency, leading to ovarian cancer.
Urinary incontinence and abdominal pain are key symptoms of ovarian cancer, with crampy abdominal pain being the most common symptom. The study found that women often ignore or downplay these symptoms, leading to delayed diagnosis.
Researchers used gene expression profiling to develop a prognostic profile for ovarian cancer, identifying 115 genes that provide important information about prognosis. This technology holds promise for understanding the root causes of ovarian cancer and designing targeted therapies.
BRCA1 mutations are found in only 5% of breast and ovarian cancers, but loss-of-function mutations can significantly increase cancer risk. Researchers review preclinical and clinical evidence to determine if BRCA1 function can predict chemotherapy response, highlighting the need for prospective studies.
A large population study has found that most ovarian cancers in families with at least one woman with breast cancer are not related to BRCA1/2 mutations. Instead, other factors may contribute to the increased risk of ovarian cancer in these families.
A review of ovarian cancer treatment controversies highlights potential caveats in the current standard first-line therapy. The study suggests that optimal management questions remain, including the effectiveness of doublet platinum-cyclophosphamide and higher doses.
In a breakthrough procedure, doctors have successfully transplanted a healthy ovary from a patient's body into her upper arm, preserving her fertility. The innovative technique uses brachial vessels to establish blood supply and has shown promising results in maintaining cyclical follicular growth.
Dr. Lancaster's presentation at the IGCS conference used microarray analysis to predict response to platinum-based chemotherapy for advanced stage epithelial ovarian cancers. The study aimed to individualize therapy for patients with advanced ovarian cancer, showcasing Moffitt's expertise in gynecologic cancer research.